![Pfizer image](https://groundnews.b-cdn.net/interests/0e9ed877d51e233b8a73f27b679f2db1a3261628.jpg)
News from Pfizer
Stay current with all the latest and breaking news about Pfizer, compare headlines and perspectives between news sources on stories happening today. In total, 327 stories have been published about Pfizer which Ground News has aggregated in the past 3 months.
Covered Most By
Suggest a source
Looking for a source we don't already have? Suggest one here.Top Pfizer News
Latest News Stories
PfizerFreeport-McMoRan is Bryn Talkington's "final trade." On July 23, Freeport-McMoRan said second-quarter revenue came in at $6.62 billion.See the Story
Freeport-McMoRan, Pfizer, Danaher And An Industrial Stock: CNBC's 'Final Trades' - Freeport-McMoRan (NYSE:FCX), Danaher (NYSE:DHR)
100% Center coverage: 1 sources
Vaccines · HungaryThe British health authority announced that it has authorized the updated Covid-19 vaccine developed by Pfizer and BioNTech. The new vaccine specifically provides protection against the JN.1 coronavirus variant and can be used for infants, children, and adults.See the Story
The manufacturer of the Pfizer vaccine has received very good news
Pfizer · United StatesThe hemophilia A treatment could become the company's second gene therapy to enter the U.S. market after Beqvez, which was cleared in April for hemophilia B.See the Story
Pfizer's gene therapy for rare genetic bleeding disorder succeeds in late-stage trial
100% Center coverage: 1 sources
Pfizer · SingaporeSINGAPORE: Pfizer’s new S$1 billion (US$743 million) expanded facility in Tuas will create over 250 "highly skilled jobs" including roles in production, quality and engineering. The extension of the company's Active Pharmaceutical Ingredient (API) manufacturing facility at Tuas Biomedical ParkSee the Story
Pfizer's new S$1 billion facility extension opens in Tuas, to create over 250 jobs
100% Center coverage: 1 sources
Pfizer · New YorkTuesday, GSK Plc (NYSE:GSK) / Pfizer Inc (NYSE:PFE)-owned ViiV Healthcare said its two-drug HIV regimen Dovato was as effective as Gilead Science Inc‘s (NASDAQ:GILD) three-drug combo Biktarvy in a head-to-head trial. Japanese pharmaceutical company Shionogi & Company is also a stakeholder in ViiV healthcare. ViiV Healthcare released 48-week findings from PASO DOBLE (GeSIDA 11720 study), the largest head-to-head, phase IV randomized clinical tria…See the Story
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial - GSK (NYSE:GSK), Pfizer (NYSE:PFE)
100% Center coverage: 1 sources